Theseus Pharmaceuticals, Inc. financial data

Industry
Pharmaceutical Preparations
Location
314 Main Street, Suite 04 200, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2023 - Nov 17, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.68K %
Debt-to-equity 5.05 % +33.9%
Return On Equity -24.8 % -27.1%
Return On Assets -23.6 % -25.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44.2M shares +14.3%
Common Stock, Shares, Outstanding 43.6M shares +12.6%
Entity Public Float 85.6M USD
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 43.8M shares +13.5%
Weighted Average Number of Shares Outstanding, Diluted 43.8M shares +13.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 47.2M USD +55.7%
General and Administrative Expense 19.3M USD +14%
Operating Income (Loss) -66.5M USD -40.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -56.6M USD -24.3%
Earnings Per Share, Basic -1.35 USD/shares -110%
Earnings Per Share, Diluted -1.35 USD/shares -110%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 46.9M USD -59.4%
Other Assets, Current 202M USD -18.5%
Assets, Current 210M USD
Property, Plant and Equipment, Net 414K USD -2.59%
Operating Lease, Right-of-Use Asset 3.92M USD -12.2%
Other Assets, Noncurrent 399K USD -78.6%
Assets 235M USD +1.88%
Accounts Payable, Current 1.31M USD -27.8%
Employee-related Liabilities, Current 2.84M USD
Accrued Liabilities, Current 4.93M USD
Liabilities, Current 7M USD -10.3%
Operating Lease, Liability, Noncurrent 2.9M USD -13.3%
Liabilities 10.1M USD -13.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -345K USD +37.3%
Retained Earnings (Accumulated Deficit) -155M USD -57.5%
Stockholders' Equity Attributable to Parent 225M USD +2.71%
Liabilities and Equity 235M USD +1.88%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.6M USD -142%
Net Cash Provided by (Used in) Financing Activities 49.5M USD
Net Cash Provided by (Used in) Investing Activities -15.8M USD +82.6%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 43.6M shares +12.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 15.1M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 47.3M USD -59.2%
Deferred Tax Assets, Valuation Allowance 25.5M USD +122%
Deferred Tax Assets, Gross 26.8M USD +133%
Operating Lease, Liability 3.66M USD -11.2%
Depreciation 20.2K USD +1915%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -56.4M USD -22.4%
Lessee, Operating Lease, Liability, to be Paid 4.65M USD -14.8%
Property, Plant and Equipment, Gross 528K USD +15.8%
Operating Lease, Liability, Current 759K USD -2.57%
Lessee, Operating Lease, Liability, to be Paid, Year Two 821K USD +3.01%
Lessee, Operating Lease, Liability, to be Paid, Year One 797K USD +2.97%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 998K USD -25.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 846K USD +3.05%
Deferred Tax Assets, Operating Loss Carryforwards 13M USD +37.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 846K USD +2.3%
Additional Paid in Capital 380M USD +19.6%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 25.5M USD +122%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%